In the Spotlight...
Epigenetic tuning of PD-1 expression improves exhausted T cell function and viral control
CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8+ T cells via JAK2/STAT3 pathway
Intratumoral radiation dose heterogeneity augments antitumor immunity in mice and primes responses to checkpoint blockade
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
Previous Digests
A sweet spot in the spleen for immune checkpoint blockade responses
September 25, 2024
Immune checkpoint blockade unleashes powerful antitumor T cell responses, but exactly which T cell states are involved and from which anatomic locations they emerge are not fully understood. Investigating these topics, Morgan, Horton, Bhandarkar, et al. profiled T cells...
Flipping the script: reprogramming tumor cells into DCs
September 18, 2024
Type 1 conventional dendritic cells (cDC1s) are required for T cell-mediated tumor regression and response to immune checkpoint blockade (ICB) in cancer. However, current immunotherapy strategies are not focused on exploiting key aspects of cDC1 functionality in vivo, such...
Age is more than just a number in cancer immunotherapy
September 11, 2024
Age-related changes to the immune system contribute to increased cancer progression and resistance to immunotherapy in older patients. Investigating this, Georgiev and Han et al. recently found that tumors grew more rapidly in aged mice due to impaired cytotoxic...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
About ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ed Fritsch
Ute Burkhardt
Lauren Hitchings
Gaelle Lespinasse-Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Paula Hochman
Shishir Pant
Nathan Suek
Morgan Janes
TESTIMONIALS
I am pleased to voice my support for the mission of ACIR to keep cancer immunotherapy researchers up to date with the current advancements in the field. Given the magnitude of new information emerging from this field, I particularly appreciate their efforts to both identify and highlight the key advancements each week and to distill the new information to key take-away points that can be easily grasped.
Professor of Medicine, Harvard Medical School; Director, MGH Center for Cancer Immunology; Institute Member, Broad Institute of Harvard and MIT
Current Sponsors
